Andrew Anagnost Acquires 1,211 HUBS Shares

Andrew Anagnost recently bought 1,211 shares of HUBS on June 16, 2026. The shares were acquired at a transaction price of $0, though the stock was trading at $182.85 on that day. This transaction is part of a broader trend of insider buying at the company.

Insider Buying and Selling at HUBS

Several insiders at HUBS, including Michael Berry, Jay Simons, Brian Halligan, Jill Ward, Claire D'Oyly-Hughes Johnson, and Lorrie Norrington, also purchased 1,211 shares each on June 16, 2026. These transactions were not part of any pre-planned trading programs.

Other Institutional Activity in HUBS

In recent institutional activity, Price T Rowe Associates added 23,975 shares to its position, bringing its total to about 4.61 million shares valued at $1.12 billion. BlackRock increased its stake by 262,272 shares, now holding roughly 4.10 million shares worth approximately $1 billion. Vanguard Portfolio Management and Vanguard Capital Management both made significant adjustments, with the former adding around 2.86 million shares. JPMorgan Chase significantly boosted its holdings by 389,346 shares, now totaling 2.66 million shares valued at $631.46 million.

Analysts Set New Price Targets

On May 11, 2026, Barclays maintained its buy rating on HUBS with a price target of $270. Earlier in May, Macquarie downgraded the stock to a hold with a $190 target. UBS, JP Morgan, and Truist Securities all maintained buy ratings, with JP Morgan setting a notably high target of $425. Citigroup and Cantor Fitzgerald also downgraded HUBS to hold, with targets of $230 and $200, respectively.

About HUBS

HUBS is a company known for its software solutions that help businesses manage customer interactions and data. It provides a suite of tools for marketing, sales, and customer service, aimed at improving customer engagement and business efficiency. HUBS is headquartered in Cambridge, Massachusetts.

Bottom Line

Andrew Anagnost's purchase of HUBS shares is part of a wave of insider buying, suggesting confidence in the company's prospects. Institutional investors have also been active, with major funds like BlackRock and JPMorgan Chase adjusting their positions. However, analyst opinions are mixed, with some firms maintaining buy ratings while others have downgraded the stock. As always, it's important to remember that insider and institutional transactions are backward-looking and may not reflect current positions.